Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Estrella Immunopharma, Inc. (ESLA) had Return on Tangible Equity of 90.95% for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
$-5.54M |
|
-- |
|
-- |
|
$5.54M |
|
$-5.54M |
|
-- |
|
$-5.54M |
|
$-5.54M |
|
$-5.54M |
|
$-5.54M |
|
$-5.54M |
|
$-5.54M |
|
$-5.54M |
|
$-5.54M |
|
36.17M |
|
36.17M |
|
$-0.15 |
|
$-0.15 |
|
| Balance Sheet Financials | |
$1.48M |
|
-- |
|
$1.50M |
|
$2.98M |
|
$9.08M |
|
-- |
|
-- |
|
$9.08M |
|
$-6.09M |
|
$-6.09M |
|
$-6.09M |
|
37.07M |
|
| Cash Flow Statement Financials | |
$-0.88M |
|
-- |
|
$1.28M |
|
$0.92M |
|
$1.32M |
|
$0.40M |
|
$0.32M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.16 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-0.88M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
90.95% |
|
|
Return on Tangible Equity |
90.95% |
-185.98% |
|
90.95% |
|
$-0.16 |
|
$-0.02 |
|
$-0.02 |
|